Evidence map›Paper›PMID 9234717›Full record

ArticleMolecular and cellular biology1997

Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity.

D P Bonita, S Miyake, M L Lupher, W Y Langdon, H Band

Abstract read
In one paragraph

Article in Molecular and cellular biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 118 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Review
  8. Review
  9. Article
  10. Review
  11. Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins.Biochemistry and analytical biochemistry : current research · 2012
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

D P BonitaDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
S Miyake
M L Lupher
W Y Langdon
H Band
Brigham and Women's Hospital · USHarvard University · USUniversity of Western Australia · AU

Funding

VALIDATION OF SELF REPORTED OSTEOARTHRITIS IN THE NURSES HEALTH STUDY COHORTP60AR036308 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI KATZ, JEFFREY NEIL · 1986 to 2000
$1.5M
TCR SIGNALLING AND FYN SH3/SH2 INTERACTIONR01CA064503 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BAND, HAMID · 1996 to 1998
–
TCR SIGNALLING AND FYN SH3-SH2 INTERACTIONR55CA064503 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BAND, HAMID · 1995 to 1995
–
NCI NIH HHS CA64503NIAMS NIH HHS AR36308
6 · The paper itself

Abstract

Recent studies have demonstrated that Cbl, the 120-kDa protein product of the c-cbl proto-oncogene, serves as a substrate of a number of receptor-coupled tyrosine kinases and forms complexes with SH3 and SH2 domain-containing proteins, pointing to its role in signal transduction. Based on genetic evidence that the Caenorhabditis elegans Cbl homolog, SLI-1, functions as a negative regulator of the LET-23 receptor tyrosine kinase and our demonstration that Cbl's evolutionarily conserved N-terminal transforming region (Cbl-N; residues 1 to 357) harbors a phosphotyrosine binding (PTB) domain that binds to activated ZAP-70 tyrosine kinase, we examined the possibility that oncogenic Cbl mutants may activate mitogenic signaling by deregulating cellular tyrosine kinase machinery. Here, we show that expression of Cbl-N and two other transforming Cbl mutants (CblY368 delta and Cbl366-382 delta or Cb170Z), but not wild-type Cbl, in NIH 3T3 fibroblasts leads to enhancement of endogenous tyrosine kinase signaling. We identified platelet-derived growth factor receptor alpha (PDGFR alpha) as one target of mutant Cbl-induced deregulation. In mutant Cbl transfectants, PDGFR alpha was hyperphosphorylated and constitutively complexed with a number of SH2 domain-containing proteins. PDGFR alpha hyperphosphorylation and enhanced proliferation of mutant Cbl-transfected NIH 3T3 cells were drastically reduced upon serum starvation, and PDGF-AA substituted for the maintenance of these traits. PDGF-AA stimulation of serum-starved Cbl transfectants induced the in vivo association of transfected Cbl proteins with PDGFR alpha. In vitro, Cbl-N directly bound to PDGFR alpha derived from PDGF-AA-stimulated cells but not to that from unstimulated cells, and this binding was abrogated by a point mutation (G306E) corresponding to a loss-of-function mutation in SLI-1. The Cbl-N/G306E mutant protein, which failed to induce enhanced growth and transformation of NIH 3T3 cells, also failed to induce hyperphosphorylation of PDGFR alpha. Altogether, these findings identify a novel mechanism of Cbl's physiological function and oncogenesis, involving its PTB domain-dependent direct interaction with cellular tyrosine kinases.

Indexed as

Ubiquitin-Protein Ligases3T3 CellsAnimalsCell DivisionCell Transformation, NeoplasticHumansMiceMutationPhosphoproteinsPhosphorylationPhosphotyrosinePlatelet-Derived Growth FactorProtein-Tyrosine KinasesProto-Oncogene MasProto-Oncogene ProteinsProto-Oncogene Proteins c-cblCBL protein, humanCbl protein, mouseMAS1 protein, humanPhosphoproteinsPhosphotyrosinePlatelet-Derived Growth Factorplatelet-derived growth factor AProtein-Tyrosine KinasesProto-Oncogene MasProto-Oncogene ProteinsProto-Oncogene Proteins c-cblReceptor, Platelet-Derived Growth Factor alphaReceptors, Platelet-Derived Growth FactorUbiquitin-Protein Ligases

Identifiers

PMID9234717
PMCPMC232313
OpenAlexW2147476448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.